Literature DB >> 32193336

Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Samanta Sharma1,2, Tian Zhang3, Wojciech Michowski1,2, Vito W Rebecca4, Min Xiao4, Roberta Ferretti5,6, Jan M Suski1,2, Roderick T Bronson7, Joao A Paulo3, Dennie Frederick8, Anne Fassl1,2, Genevieve M Boland8, Yan Geng1,2, Jacqueline A Lees5,9, Rene H Medema10, Meenhard Herlyn4, Steven P Gygi3, Piotr Sicinski11,2.   

Abstract

The cyclin-dependent kinase 5 (CDK5), originally described as a neuronal-specific kinase, is also frequently activated in human cancers. Using conditional CDK5 knockout mice and a mouse model of highly metastatic melanoma, we found that CDK5 is dispensable for the growth of primary tumors. However, we observed that ablation of CDK5 completely abrogated the metastasis, revealing that CDK5 is essential for the metastatic spread. In mouse and human melanoma cells CDK5 promotes cell invasiveness by directly phosphorylating an intermediate filament protein, vimentin, thereby inhibiting assembly of vimentin filaments. Chemical inhibition of CDK5 blocks the metastatic spread of patient-derived melanomas in patient-derived xenograft (PDX) mouse models. Hence, inhibition of CDK5 might represent a very potent therapeutic strategy to impede the metastatic dissemination of malignant cells.

Entities:  

Keywords:  CDK5; cyclin-dependent kinases; metastasis; mouse cancer models

Mesh:

Substances:

Year:  2020        PMID: 32193336      PMCID: PMC7149478          DOI: 10.1073/pnas.1912617117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  78 in total

Review 1.  Cdk5 regulates multiple cellular events in neural development, function and disease.

Authors:  Takeshi Kawauchi
Journal:  Dev Growth Differ       Date:  2014-05-21       Impact factor: 2.053

2.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Authors:  Bradley Garman; Ioannis N Anastopoulos; Clemens Krepler; Patricia Brafford; Katrin Sproesser; Yuchao Jiang; Bradley Wubbenhorst; Ravi Amaravadi; Joseph Bennett; Marilda Beqiri; David Elder; Keith T Flaherty; Dennie T Frederick; Tara C Gangadhar; Michael Guarino; David Hoon; Giorgos Karakousis; Qin Liu; Nandita Mitra; Nicholas J Petrelli; Lynn Schuchter; Batool Shannan; Carol L Shields; Jennifer Wargo; Brandon Wenz; Melissa A Wilson; Min Xiao; Wei Xu; Xaiowei Xu; Xiangfan Yin; Nancy R Zhang; Michael A Davies; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

3.  Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.

Authors:  Christopher J Strock; Jong-In Park; Eric K Nakakura; G Steven Bova; John T Isaacs; Douglas W Ball; Barry D Nelkin
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 4.  The role of B-RAF in melanoma.

Authors:  Vanessa C Gray-Schopfer; Silvy da Rocha Dias; Richard Marais
Journal:  Cancer Metastasis Rev       Date:  2005-01       Impact factor: 9.264

5.  Vimentin function in lymphocyte adhesion and transcellular migration.

Authors:  Mikko Nieminen; Tiina Henttinen; Marika Merinen; Fumiko Marttila-Ichihara; John E Eriksson; Sirpa Jalkanen
Journal:  Nat Cell Biol       Date:  2006-01-22       Impact factor: 28.824

6.  A chemical switch for inhibitor-sensitive alleles of any protein kinase.

Authors:  A C Bishop; J A Ubersax; D T Petsch; D P Matheos; N S Gray; J Blethrow; E Shimizu; J Z Tsien; P G Schultz; M D Rose; J L Wood; D O Morgan; K M Shokat
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

7.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.

Authors:  R Dixon Dorand; Joseph Nthale; Jay T Myers; Deborah S Barkauskas; Stefanie Avril; Steven M Chirieleison; Tej K Pareek; Derek W Abbott; Duncan S Stearns; John J Letterio; Alex Y Huang; Agne Petrosiute
Journal:  Science       Date:  2016-07-21       Impact factor: 47.728

8.  Intermediate filament reconstitution in vitro. The role of phosphorylation on the assembly-disassembly of desmin.

Authors:  M Inagaki; Y Gonda; M Matsuyama; K Nishizawa; Y Nishi; C Sato
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

9.  Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.

Authors:  Savita Bisht; Jens Nolting; Ute Schütte; Jens Haarmann; Prashi Jain; Dhruv Shah; Peter Brossart; Patrick Flaherty; Georg Feldmann
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

10.  An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.

Authors:  Kanglai Wei; Zhihua Ye; Zuyun Li; Yiwu Dang; Xin Chen; Na Huang; Chongxi Bao; Tingqing Gan; Lihua Yang; Gang Chen
Journal:  World J Surg Oncol       Date:  2016-02-09       Impact factor: 2.754

View more
  6 in total

1.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

2.  O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation.

Authors:  Lorela Ciraku; Zachary A Bacigalupa; Jing Ju; Rebecca A Moeller; Giang Le Minh; Rusia H Lee; Michael D Smith; Christina M Ferrer; Sophie Trefely; Luke T Izzo; Mary T Doan; Wiktoria A Gocal; Luca D'Agostino; Wenyin Shi; Joshua G Jackson; Christos D Katsetos; Kathryn E Wellen; Nathaniel W Snyder; Mauricio J Reginato
Journal:  Oncogene       Date:  2022-02-22       Impact factor: 8.756

3.  Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice.

Authors:  Benjamin Thilo Krüger; Lena Steppe; Sabine Vettorazzi; Melanie Haffner-Luntzer; Sooyeon Lee; Ann-Kristin Dorn; Anita Ignatius; Jan Tuckermann; Mubashir Ahmad
Journal:  Biomedicines       Date:  2022-02-08

Review 4.  Post-translational modifications of CDK5 and their biological roles in cancer.

Authors:  Gui-Bin Gao; Yue Sun; Run-Dong Fang; Ying Wang; Yang Wang; Qing-Yu He
Journal:  Mol Biomed       Date:  2021-07-20

Review 5.  Three decades of Cdk5.

Authors:  Ping-Chieh Pao; Li-Huei Tsai
Journal:  J Biomed Sci       Date:  2021-11-23       Impact factor: 8.410

6.  Identifying FBLN1 (Gene ID: 2192) as a Potential Melanoma Biomarker for Melanoma based on an Analysis of microRNA Expression Profiles in the GEO and TCGA Databases.

Authors:  Xiao-Tian Liu; Tian-Tian Liu; Meng-Yuan Wu; Qing-Xi Chen; Jiang-Xing Zhuang; Qin Wang
Journal:  Genet Test Mol Biomarkers       Date:  2021-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.